Commitments and Contingencies (Details) - USD ($) |
1 Months Ended | 12 Months Ended | |
|---|---|---|---|
Sep. 30, 2022 |
Dec. 31, 2022 |
Dec. 31, 2021 |
|
| Commitments and Contingencies (Details) [Line Items] | |||
| Rent expense for space | $ 13,080 | ||
| Rent expense | $ 400,000 | $ 400,000 | |
| 2011 Exclusive Agreement [Member] | |||
| Commitments and Contingencies (Details) [Line Items] | |||
| Milestone payment | $ 765,000 | ||
| License reduced percentage | 50.00% | ||
| Aggregate maintenance fees | $ 80,000 | ||
| Maintenance fees annually | $ 50,000 | ||
| Percentage of worldwide net sales | 2.00% | ||
| Subject to a minimum royalty payment | $ 75,000 | ||
| Royalty description | The Company is required to pay royalties ranging from 8% of worldwide sublicense sales of covered products (if the sublicense is entered after commencement of Phase II clinical trials) to 12% of worldwide sublicense sales (if the sublicense is entered prior to commencement of Phase I clinical trials). | ||
| 2013 Exclusive Agreement [Member] | |||
| Commitments and Contingencies (Details) [Line Items] | |||
| Milestone payment | $ 765,000 | ||
| License reduced percentage | 50.00% | ||
| Percentage of worldwide net sales | 2.00% | ||
| Subject to a minimum royalty payment | $ 75,000 | ||
| Royalty description | The Company is required to pay the Regents royalties ranging from 8% of worldwide sublicense sales of covered products (if the sublicense is entered after commencement of Phase II clinical trials) to 12% of worldwide sublicense sales (if the sublicense is entered prior to commencement of Phase I clinical trials). | ||
| Initial license issue fee | $ 10,000 | ||
| Aggregate maintenance fees | 7,500 | ||
| Maintenance fees annually | $ 5,000 | ||
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of maintenance fees. No definition available.
|
| X | ||||||||||
- Definition Amount of payments aggregating. No definition available.
|
| X | ||||||||||
- Definition Percentage of payments for additional products developed and sold. No definition available.
|
| X | ||||||||||
- Definition Percentage of worldwide net sales. No definition available.
|
| X | ||||||||||
- Definition Amount of rent expense for space. No definition available.
|
| X | ||||||||||
- Definition RoyaltyDescription. No definition available.
|
| X | ||||||||||
- Definition Amount of expense for administrative services provided to the limited liability company (LLC) or limited partnership (LP) by the managing member or general partner, affiliate of managing member or general partner, or affiliate of LLC or LP, for example, but not limited to, salaries, rent, or overhead costs. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Cost of maintenance incurred and directly related to good produced and service rendered. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of tax incurred and cost of license directly related to good produced or service rendered. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Cash payments to lessor's for use of assets under operating leases. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|